Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Opinions Illness Primers. 2018;4:1–20.
Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild MJ, Bohlius J, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25:1200–12.
Hosseini-Moghaddam SM, Ouédraogo A, Naylor KL, Bota SE, Husain S, Nash DM, Paterson JM. Incidence and outcomes of invasive fungal an infection amongst strong organ transplant recipients: a inhabitants‐primarily based cohort examine. Transpl Infect Illness. 2020;22:13250.
Denning DW. International incidence and mortality of extreme fungal illness. Lancet Infect Dis. 2024;24:428–38.
Liu N, Zhou J, Jiang T, Tarsio M, Yu F, Zheng X, Qi W, Liu L, Tan J, Wei L, et al. A twin motion small molecule enhances azoles and overcomes resistance via co-targeting Pdr5 and Vma1: Osimertinib targets Pdr5 and Vma1. Translational Analysis: J Lab Clin Med. 2022;247:39–57.
Liu N-N, Zhou J, Jiang T, Tarsio M, Yu F, Zheng X, Qi W, Liu L, Tan J-c, Wei L. A twin motion small molecule enhances azoles and overcomes resistance via co-targeting Pdr5 and Vma1. Translational Res. 2022;247:39–57.
Calderone RA, Fonzi WA. Virulence elements of Candida albicans. Tendencies Microbiol. 2001;9:327–35.
Wenzel RP. Nosocomial candidemia: danger elements and attributable mortality. Clin Infect Dis. 1995;20:1531–4.
Enoch DA, Yang H, Aliyu SH, Micallef C. The altering epidemiology of invasive fungal infections. Hum Fungal Pathogen Identification: Strategies Protocols. 2017;10:17–65.
Roemer T, Krysan DJ. Antifungal drug improvement: challenges, unmet medical wants, and new approaches. Chilly Spring Harbor Perspect Med. 2014;4:a019703.
Lombardi T, Budtz-Jørgensen E. Therapy of denture-induced stomatitis: a evaluate. Eur J Prosthodont Restor Dent. 1993;2:17–22.
Nett JE, Andes DR. Antifungal brokers: spectrum of exercise, pharmacology, and medical indications. Infect Illness Clin. 2016;30:51–83.
Onishi J, Meinz M, Thompson J, Curotto J, Dreikorn S, Rosenbach M, Douglas C, Abruzzo G, Flattery A, Kong L. Discovery of novel antifungal (1, 3)-β-D-glucan synthase inhibitors. Antimicrob Brokers Chemother. 2000;44:368–77.
Beyda ND, Lewis RE, Garey KW. Echinocandin resistance in Candida species: mechanisms of decreased susceptibility and therapeutic approaches. Ann Pharmacother. 2012;46:1086–96.
Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, Bromley M, Brüggemann R, Garber G, Cornely OA. Tackling the rising risk of antifungal resistance to human well being. Nat Rev Microbiol. 2022;20:557–71.
Donnelly RF, McCarron PA, Tunney MM. Antifungal photodynamic remedy. Microbiol Res. 2008;163:1–12.
Butts A, Krysan DJ. Antifungal drug discovery: one thing outdated and one thing new. PLoS Pathog. 2012;8:e1002870.
Stone NR, Bicanic T, Salim R, Hope W. Liposomal amphotericin B (AmBisome®): a evaluate of the pharmacokinetics, pharmacodynamics, medical expertise and future instructions. Medicine. 2016;76:485–500.
Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, Rutakingirwa MK, Ssebambulidde Ok, Tugume L, Rhein J. Single-dose liposomal amphotericin B therapy for cryptococcal meningitis. N Engl J Med. 2022;386:1109–20.
Liu Q, Zou J, Chen Z, He W, Wu W. Present analysis developments of nanomedicines. Acta Pharm Sinica B. 2023;13:4391–416.
Leenders A, Marie S. The usage of lipid formulations of amphotericin B for systemic fungal infections. Leukemia. 1996;10:1570–5.
Cheeseman S, Christofferson AJ, Kariuki R, Cozzolino D, Daeneke T, Crawford RJ, Truong VK, Chapman J, Elbourne A. Antimicrobial metallic nanomaterials: from passive to stimuli-activated functions. Adv Sci. 2020;7:1902913.
Araujo VHS, Duarte JL, Carvalho GC, Silvestre ALP, Fonseca-Santos B, Marena GD, Ribeiro TC, dos Santos Ramos MA, Bauab TM, Chorilli M. Nanosystems in opposition to candidiasis: a evaluate of research carried out over the past 20 years. Crit Rev Microbiol. 2020;46:508–47.
Li B, Pan L, Zhang H, Xie L, Wang X, Shou J, Qi Y, Yan X. Latest developments on utilizing nanomaterials to fight Candida albicans. Entrance Chem. 2021;9:813973.
Huang Y, Guo X, Wu Y, Chen X, Feng L, Xie N, Shen G. Nanotechnology’s frontier in combatting infectious and inflammatory ailments: prevention and therapy. Sign Transduct Goal Remedy. 2024;9:34.
Choi V, Rohn JL, Stoodley P, Carugo D, Stride E. Drug supply methods for antibiofilm remedy. Nat Rev Microbiol. 2023;21:555–72.
DeQueiroz G, Day D. Antimicrobial exercise and effectiveness of a mixture of sodium hypochlorite and hydrogen peroxide in killing and eradicating Pseudomonas aeruginosa biofilms from surfaces. J Appl Microbiol. 2007;103:794–802.
Berman J, Krysan DJ. Drug resistance and tolerance in fungi. Nat Rev Microbiol. 2020;18:319–31.
Costerton JW, Cheng Ok, Geesey GG, Ladd TI, Nickel JC, Dasgupta M, Marrie TJ. Bacterial biofilms in nature and illness. Annual Opinions Microbiol. 1987;41:435–64.
Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a typical reason for persistent infections. Science. 1999;284:1318–22.
Davis SC, Martinez L, Kirsner R. The diabetic foot: the significance of biofilms and wound mattress preparation. Curr Diab Rep. 2006;6:439–45.
Smith AW. Biofilms and antibiotic remedy: is there a job for combating bacterial resistance by way of novel drug supply methods? Adv Drug Deliv Rev. 2005;57:1539–50.
Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: improvement, structure, and drug resistance. J Bacteriol. 2001;183:5385–94.
Nett JE, Crawford Ok, Marchillo Ok, Andes DR. Function of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Brokers Chemother. 2010;54:3505–8.
Al-Fattani MA, Douglas LJ. Penetration of Candida biofilms by antifungal brokers. Antimicrob Brokers Chemother. 2004;48:3291–7.
Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ. Impression of therapy technique on outcomes in sufferers with candidemia and different types of invasive candidiasis: a patient-level quantitative evaluate of randomized trials. Clin Infect Dis. 2012;54:1110–22.
Liu C, Wu H, Xu Ok. Photodynamic remedy and the appliance of antitumor immunotherapy for tumor therapy. Zhongguo Zhong Liu Lin Chuang. 2021;48:35–9.
Jia Q, Tune Q, Li P, Huang W. Rejuvenated photodynamic remedy for bacterial infections. Adv Healthc Mater. 2019;8:1900608.
Zhou C, Peng C, Shi C, Jiang M, Chau JH, Liu Z, Bai H, Kwok RT, Lam JW, Shi Y. Mitochondria-specific aggregation-induced emission luminogens for selective photodynamic killing of fungi and efficacious therapy of keratitis. ACS Nano. 2021;15:12129–39.
Tang N, Yuan S, Luo Y, Wang A-J, Solar Ok, Liu N-N, Tao Ok. Nanoparticle-based photodynamic inhibition of Candida albicans Biofilms with Interfering Quorum sensing. ACS Omega. 2023;8:4357–68.
Kovács R, Majoros L. Fungal quorum-sensing molecules: a evaluate of their antifungal impact in opposition to Candida biofilms. J Fungi. 2020;6:99.
Maliszewska I, Lisiak B, Popko Ok, Matczyszyn Ok. Enhancement of the efficacy of photodynamic inactivation of Candida albicans with using biogenic gold nanoparticles. Photochem Photobiol. 2017;93:1081–90.
Madkhali OA. A complete evaluate on potential functions of metallic nanoparticles as antifungal therapies to fight human fungal ailments. Saudi Pharm J. 2023;31:101733.
Zhao X, Tang H, Jiang X. Deploying gold nanomaterials in combating multi-drug-resistant micro organism. ACS Nano. 2022;16:10066–87.
Tabassum N, Khan F, Kang M-G, Jo D-M, Cho Ok-J, Kim Y-M. Inhibition of Polymicrobial Biofilms of Candida albicans–Staphylococcusaureus/Streptococcus mutans by Fucoidan–Gold Nanoparticles. Mar Medicine. 2023;21:123.
He J, Ye Y, Zhang D, Yao Ok, Zhou M. Visualized Gallium/Lyticase-Built-in Antifungal Technique for Fungal Keratitis Therapy. Adv Mater. 2022;34:2206437.
Good JR. The antifungal pipeline: a actuality test. Nat Rev Drug Discovery. 2017;16:603–16.
Anderson TM, Clay MC, Cioffi AG, Diaz KA, Hisao GS, Tuttle MD, Nieuwkoop AJ, Comellas G, Maryum N, Wang S. Amphotericin kinds an extramembranous and fungicidal sterol sponge. Nat Chem Biol. 2014;10:400–6.
Letscher-Bru V, Herbrecht R. Caspofungin: the primary consultant of a brand new antifungal class. J Antimicrob Chemother. 2003;51:513–21.
Lee Y, Puumala E, Robbins N, Cowen LE. Antifungal drug resistance: molecular mechanisms in Candida albicans and past. Chem Rev. 2020;121:3390–411.
Gao J, Wang H, Li Z, Wong AH-H, Wang Y-Z, Guo Y, Lin X, Zeng G, Liu H, Wang Y. Candida albicans good points azole resistance by altering sphingolipid composition. Nat Commun. 2018;9:4495.
Lemke A, Kiderlen A, Kayser O. Amphotericin b. Appl Microbiol Biotechnol. 2005;68:151–62.
Rao L, Tian R, Chen X. Cell-membrane-mimicking nanodecoys in opposition to infectious ailments. ACS Nano. 2020;14:2569–74.
Sprint P, Piras AM, Sprint M. Cell membrane coated nanocarriers-an environment friendly biomimetic platform for focused remedy. J Managed Launch. 2020;327:546–70.
Liu Y, Luo J, Chen X, Liu W, Chen T. Cell membrane coating know-how: a promising technique for biomedical functions. Nano-Micro Lett. 2019;11:1–46.
Xie J, Shen Q, Huang Ok, Zheng T, Cheng L, Zhang Z, et al. Oriented meeting of cell-mimicking nanoparticles by way of a molecular affinity technique for focused drug supply. ACS Nano. 2019;13:5268–77.
Li B, Wang W, Zhao L, Wu Y, Li X, Yan D, Gao Q, Yan Y, Zhang J, Feng Y. Photothermal remedy of tuberculosis utilizing focusing on pre-activated macrophage membrane-coated nanoparticles. Nat Nanotechnol. 2024;19:834–45.
Zhu J, Xie R, Gao R, Zhao Y, Yodsanit N, Zhu M, et al. Multimodal nanoimmunotherapy engages neutrophils to eradicate Staphylococcus aureus infections. Nat Nanotechnol 2024;19:1032–43.
Deerhake ME, Shinohara ML. Rising roles of Dectin-1 in noninfectious settings and within the CNS. Tendencies Immunol. 2021;42:891–903.
Brown GD. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol. 2006;6:33–43.
Ambati S, Ferarro AR, Kang SE, Lin J, Lin X, Momany M, Lewis ZA, Meagher RB. Dectin-1-targeted antifungal liposomes exhibit enhanced efficacy. MSphere. 2019;4:e00025–00019.
Krishnan N, Fang RH, Zhang L. Engineering of stimuli-responsive self-assembled biomimetic nanoparticles. Adv Drug Deliv Rev. 2021;179:114006.
Fatima M, Almalki WH, Khan T, Sahebkar A, Kesharwani P. Harnessing the facility of Stimuli-Responsive nanoparticles as an efficient therapeutic drug supply system. Adv Mater. 2024;36:2312939.
Park S-C, Kim Y-M, Lee J-Ok, Kim N-H, Kim E-J, Heo H, Lee M-Y, Lee JR, Jang M-Ok. Concentrating on and synergistic motion of an antifungal peptide in an antibiotic drug-delivery system. J Managed Launch. 2017;256:46–55.
Wang Z, Liu X, Duan Y, Huang Y. An infection microenvironment-related antibacterial nanotherapeutic methods. Biomaterials. 2022;280:121249.
Friedman AJ, Phan J, Schairer DO, Champer J, Qin M, Pirouz A, Blecher-Paz Ok, Oren A, Liu PT, Modlin RL. Antimicrobial and anti inflammatory exercise of chitosan–alginate nanoparticles: a focused remedy for cutaneous pathogens. J Make investments Dermatology. 2013;133:1231–9.
Khalaf EM, Abood NA, Atta RZ, Ramírez-Coronel AA, Alazragi R, Parra RMR, Abed OH, Abosaooda M, Jalil AT, Mustafa YF. Latest progressions in biomedical and pharmaceutical functions of chitosan nanoparticles: a complete evaluate. Int J Biol Macromol. 2023;231:123354.
Mohamed M, Fouad S, Elshoky HA, Mohammed GM, Salaheldin TA. Antibacterial impact of gold nanoparticles in opposition to Corynebacterium pseudotuberculosis. Int J Veterinary Sci Med. 2017;5:23–9.
Sirelkhatim A, Mahmud S, Seeni A, Kaus NHM, Ann LC, Bakhori SKM, Hasan H, Mohamad D. Overview on Zinc Oxide nanoparticles: antibacterial exercise and toxicity mechanism. Nano-Micro Lett. 2015;7:219–42.
Arakha M, Pal S, Samantarrai D, Panigrahi TK, Mallick BC, Pramanik Ok, Mallick B, Jha S. Antimicrobial exercise of iron oxide nanoparticle upon modulation of nanoparticle-bacteria interface. Sci Rep. 2015;5:14813.
Kubacka A, Diez MS, Rojo D, Bargiela R, Ciordia S, Zapico I, et al. Understanding the antimicrobial mechanism of TiO2-based nanocomposite movies in a pathogenic bacterium. Sci Rep 2014;4:4134.
Radhakrishnan VS, Mudiam MKR, Kumar M, Dwivedi SP, Singh SP, Prasad T. Silver nanoparticles induced alterations in a number of mobile targets, that are crucial for drug susceptibilities and pathogenicity in fungal pathogen (Candida albicans). Int J Nanomed. 2018;13:2647.
Ashrafi M, Bayat M, Mortazavi P, Hashemi SJ, Meimandipour A. Antimicrobial impact of chitosan–silver–copper nanocomposite on Candida albicans. J Nanostructure Chem. 2020;10:87–95.
Youssef A, Abd El-Aziz M, Abd El-Sayed ES, Moussa M, Turky G, Kamel S. Rational design and electrical examine of conducting bionanocomposites hydrogel primarily based on chitosan and silver nanoparticles. Int J Biol Macromol. 2019;140:886–94.
Zhang L, Pornpattananangkul D, Hu C-M, Huang C-M. Improvement of nanoparticles for antimicrobial drug supply. Curr Med Chem. 2010;17:585–94.
Huh AJ, Kwon YJ. Nanoantibiotics: a brand new paradigm for treating infectious ailments utilizing nanomaterials within the antibiotics resistant period. J Managed Launch. 2011;156:128–45.
Vincent BM, Langlois J-B, Srinivas R, Lancaster AK, Scherz-Shouval R, Whitesell L, Tidor B, Buchwald SL, Lindquist S. A fungal-selective cytochrome bc1 inhibitor impairs virulence and prevents the evolution of drug resistance. Cell Chem Biology. 2016;23:978–91.
Rex JH, Walsh TJ, Nettleman M, Anaissie EJ, Bennett JE, Bow EJ, Carillo-Munoz A, Chavanet P, Cloud GA, Denning DW. Want for various trial designs and analysis methods for therapeutic research of invasive mycoses. Clin Infect Dis. 2001;33:95–106.
Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of resistance to antifungal medication challenges human well being and meals safety. Science. 2018;360:739–42.
Healey KR, Zhao Y, Perez WB, Lockhart SR, Sobel JD, Farmakiotis D. Prevalent mutator genotype recognized in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat Commun. 2016;7:11128.
Satori CP, Henderson MM, Krautkramer EA, Kostal V, Distefano MM, Arriaga EA. Bioanalysis of eukaryotic organelles. Chem Rev. 2013;113:2733–811.
Jhaveri A, Torchilin V. Intracellular supply of nanocarriers and focusing on to subcellular organelles. Professional Opin Drug Deliv. 2016;13:49–70.
Chen WH, Luo GF, Zhang XZ. Latest advances in subcellular focused most cancers remedy primarily based on practical supplies. Adv Mater. 2019;31:1802725.
BENNETT JE: Flucytosine. Ann Intern Med. 1977;86:319–22.
Hope WW, Tabernero L, Denning DW, Anderson MJ. Molecular mechanisms of main resistance to Flucytosine in Candida albicans. Antimicrob Brokers Chemother. 2004;48:4377–86.
Hsiao CR, Huang L, Bouchara J-P, Barton R, Li HC, Chang TC. Identification of medically vital molds by an oligonucleotide array. J Clin Microbiol. 2005;43:3760–8.
Blecher Ok, Nasir A, Friedman A. The rising function of nanotechnology in combating infectious illness. Virulence. 2011;2:395–401.
Schairer DO, Chouake JS, Nosanchuk JD, Friedman AJ. The potential of nitric oxide releasing therapies as antimicrobial brokers. Virulence. 2012;3:271–9.
Qin Y, Wang J, Lv Q, Han B. Latest progress in Analysis on Mitochondrion-targeted antifungal medication: a evaluate. Antimicrob Brokers Chemother. 2023;67:e00003–00023.
Murante D, Hogan DA. New mitochondrial targets in fungal pathogens. Mbio. 2019;10:e02258–02219.
Kummer E, Ban N. Mechanisms and regulation of protein synthesis in mitochondria. Nat Rev Mol Cell Biol. 2021;22:307–25.
D’Souza GG, Weissig V. Subcellular focusing on: a brand new frontier for drug-loaded pharmaceutical nanocarriers and the idea of the magic bullet. Professional Opin Drug Deliv. 2009;6:1135–48.
Zhang D, Wen L, Huang R, Wang H, Hu X, Xing D. Mitochondrial particular photodynamic remedy by rare-earth nanoparticles mediated near-infrared graphene quantum dots. Biomaterials. 2018;153:14–26.
Piktel E, Suprewicz Ł, Depciuch J, Cieśluk M, Chmielewska S, Durnaś B, Król G, Wollny T, Deptuła P, Kochanowicz J. Rod-shaped gold nanoparticles exert potent candidacidal exercise and reduce the adhesion of fungal cells. Nanomedicine. 2020;15:2733–52.
Hwang Is, Lee J, Hwang JH, Kim KJ, Lee DG. Silver nanoparticles induce apoptotic cell dying in Candida albicans via the rise of hydroxyl radicals. FEBS J. 2012;279:1327–38.
McLellan CA, Vincent BM, Solis NV, Lancaster AK, Sullivan LB, Hartland CL, et al. Inhibiting mitochondrial phosphate transport as an unexploited antifungal technique. Nat Chem Biol. 2018;14:135–41.
Yamashita Ok, Miyazaki T, Fukuda Y, Mitsuyama J, Saijo T, Shimamura S, et al. The novel arylamidine T-2307 selectively disrupts yeast mitochondrial perform by inhibiting respiratory chain complexes. Antimicrob Brokers Chemother. 2019;63:e00374-19.
Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, et al. The novel arylamidine T-2307 maintains in vitro and in vivo exercise in opposition to echinocandin-resistant Candida albicans. Antimicrob Brokers Chemother. 2015;59:1341–3.
Wu Y, Jiang W, Cong Z, Chen Ok, She Y, Zhong C, Zhang W, Chen M, Zhou M, Shao N. An efficient technique to develop potent and selective antifungal brokers from cell penetrating peptides in tackling drug-resistant invasive fungal infections. J Med Chem. 2022;65:7296–311.
Helmerhorst EJ, Breeuwer P, van’t Hof W, Walgreen-Weterings E, Oomen LC, Veerman EC, Amerongen AVN, Abee T. The mobile goal of histatin 5 on Candida albicans is the energized mitochondrion. J Biol Chem. 1999;274:7286–91.
Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP. Most cancers metabolism: a therapeutic perspective. Nat Opinions Clin Oncol. 2017;14:11–31.
Wijnants S, Vreys J, Van Dijck P. Attention-grabbing antifungal drug targets within the central metabolism of Candida albicans. Tendencies Pharmacol Sci. 2022;43:69–79.
Chen X, Zhang Z, Chen Z, Li Y, Su S, Solar S. Potential antifungal targets primarily based on glucose metabolism pathways of Candida albicans. Entrance Microbiol. 2020;11:296.
Vesely EM, Williams RB, Konopka JB, Lorenz MC. N-Acetylglucosamine metabolism promotes survival of Candida albicans within the phagosome. Msphere. 2017;2:00357–00317.
Alves R, Mota S, Silva S, Rodrigues F, Brown CP, Henriques AJ, Casal M, Paiva M. The carboxylic acid transporters Jen1 and Jen2 have an effect on the structure and fluconazole susceptibility of Candida albicans biofilm within the presence of lactate. Biofouling. 2017;33:943–54.
Ene IV, Adya AK, Wehmeier S, Model AC, MacCallum DM, Gow NA, Brown AJ. Host carbon sources modulate cell wall structure, drug resistance and virulence in a fungal pathogen. Cell Microbiol. 2012;14:1319–35.
Ji Y, Han Z, Ding H, Xu X, Wang D, Zhu Y, An F, Tang S, Zhang H, Deng J. Enhanced eradication of bacterial/fungi biofilms by glucose oxidase-modified magnetic nanoparticles as a possible therapy for persistent endodontic infections. ACS Appl Mater Interfaces. 2021;13:17289–99.
Rodaki A, Bohovych IM, Enjalbert B, Younger T, Odds FC, Gow NA, Brown AJ. Glucose promotes stress resistance within the fungal pathogen Candida albicans. Mol Biol Cell. 2009;20:4845–55.
Dietl A-M, Misslinger M, Aguiar MM, Ivashov V, Teis D, Pfister J, et al. The siderophore transporter Sit1 determines susceptibility to the antifungal VL-2397. Antimicrob Brokers Chemother. 2019;63:e00807-19.
Nakamura I, Yoshimura S, Masaki T, Takase S, Ohsumi Ok, Hashimoto M, Furukawa S, Fujie A. ASP2397: a novel antifungal agent produced by Acremonium Persicinum MF-347833. J Antibiot. 2017;70:45–51.
Yu Q, Jia C, Dong Y, Zhang B, Xiao C, Chen Y, Wang Y, Li X, Wang L, Zhang B. Candida albicans autophagy, not a bystander: its function in tolerance to ER stress-related antifungal medication. Fungal Genet Biol. 2015;81:238–49.
Brown AJ, Brown GD, Netea MG, Gow NA. Metabolism impacts upon Candida immunogenicity and pathogenicity at a number of ranges. Tendencies Microbiol. 2014;22:614–22.
Mora-Montes HM, Bates S, Netea MG, Díaz-Jiménez DF, López-Romero E, Zinker S, Ponce-Noyola P, Kullberg BJ, Brown AJ, Odds FC. Endoplasmic reticulum α-glycosidases of Candida albicans are required for N glycosylation, cell wall integrity, and regular host-fungus interplay. Eukaryot Cell. 2007;6:2184–93.
Lecomte F, Ismail N, Excessive S. Making membrane proteins on the mammalian endoplasmic reticulum. Biochem Soc Trans. 2003;31:1248–52.
Almeida C, Amaral MD. A central function of the endoplasmic reticulum within the cell emerges from its practical contact websites with a number of organelles. Cell Mol Life Sci. 2020;77:4729–45.
Elias R, Benhamou RI, Jaber QZ, Dorot O, Zada SL, Oved Ok, Pichinuk E, Fridman M. Antifungal exercise, mode of motion variability, and subcellular distribution of coumarin-based antifungal azoles. Eur J Med Chem. 2019;179:779–90.
Benhamou RI, Jaber QZ, Herzog IM, Roichman Y, Fridman M. Fluorescent monitoring of the endoplasmic reticulum in stay pathogenic fungal cells. ACS Chem Biol. 2018;13:3325–32.
Benhamou RI, Bibi M, Berman J, Fridman M. Localizing antifungal medication to the proper organelle can markedly improve their efficacy. Angew Chem. 2018;130:6338–43.
Zhang W, Yu M, Xi Z, Nie D, Dai Z, Wang J, Qian Ok, Weng H, Gan Y, Xu L. Most cancers cell membrane-camouflaged nanorods with endoplasmic reticulum focusing on for improved antitumor remedy. ACS Appl Mater Interfaces. 2019;11:46614–25.
Wang Y, Kaur G, Chen Y, Santos A, Losic D, Evdokiou A. Bioinert anodic alumina nanotubes for focusing on of endoplasmic reticulum stress and autophagic signaling: a combinatorial nanotube-based drug supply system for enhancing most cancers remedy. ACS Appl Mater Interfaces. 2015;7:27140–51.
Shi L, Gao X, Yuan W, Xu L, Deng H, Wu C, Yang J, Jin X, Zhang C, Zhu X. Endoplasmic reticulum–focused fluorescent nanodot with giant Stokes Shift for Vesicular Transport Monitoring and long-term bioimaging. Small. 2018;14:1800223.
Ma X, Gong N, Zhong L, Solar J, Liang X-J. Way forward for nanotherapeutics: focusing on the mobile sub-organelles. Biomaterials. 2016;97:10–21.
Shi Y, Wang S, Wu J, Jin X, You J. Pharmaceutical methods for endoplasmic reticulum-targeting and their prospects of software. J Managed Launch. 2021;329:337–52.
Yang J, Griffin A, Qiang Z, Ren J. Organelle-targeted therapies: a complete evaluate on system design for enabling precision oncology. Sign Transduct Goal Remedy. 2022;7:379.
Wang J, Fang X, Liang W. Pegylated phospholipid micelles induce endoplasmic reticulum-dependent apoptosis of most cancers cells however not regular cells. ACS Nano. 2012;6:5018–30.
Cowen LE, Lindquist S. Hsp90 potentiates the Speedy Evolution of New traits: Drug Resistance in Various Fungi. Science. 2005;309:2185–9.
Schell R, Mullis M, Ehrenreich IM. Modifiers of the genotype–phenotype map: Hsp90 and past. PLoS Biol. 2016;14:e2001015.
Huang DS, Leblanc EV, Shekhar-Guturja T, Robbins N, Krysan DJ, Pizarro JC, Whitesell L, Cowen LE, Brown LE. Design and synthesis of fungal-selective resorcylate aminopyrazole Hsp90 inhibitors. J Med Chem. 2019;63:2139–80.
Whitesell L, Robbins N, Huang DS, McLellan CA, Shekhar-Guturja T, Leblanc EV, Nation CS, Hui R, Hutchinson A, Collins C, et al. Structural foundation for species-selective focusing on of Hsp90 in a pathogenic fungus. Nat Commun. 2019;10:402.
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS. Bortezomib plus Melphalan and prednisone for preliminary therapy of a number of myeloma. N Engl J Med. 2008;359:906–17.
Roemer T, Davies J, Giaever G, Nislow C. Bugs, medication and chemical genomics. Nat Chem Biol. 2012;8:46–56.
Xu D, Ondeyka J, Harris GH, Zink D, Kahn JN, Wang H, Payments G, Platas G, Wang W, Szewczak AA. Isolation, construction, and organic actions of fellutamides C and D from an undescribed Metulocladosporiella (Chaetothyriales) utilizing the genome-wide Candida albicans health take a look at. J Nat Prod. 2011;74:1721–30.
Roemer T, Xu D, Singh SB, Parish CA, Harris G, Wang H, Davies JE, Payments GF. Confronting the challenges of pure product-based antifungal discovery. Chem Biol. 2011;18:148–64.
Gutierrez-Gongora D, Geddes-McAlister J. From naturally-sourced protease inhibitors to new therapies for fungal infections. J Fungi. 2021;7:1016.
Wójcik-Mieszawska S, Lewtak Ok, Skwarek E, Dębowski D, Gitlin-Domagalska A, Nowak J, Wydrych J, Pawelec J, Fiołka MJ. Autophagy of Candida albicans cells after the motion of earthworm Venetin-1 nanoparticle with protease inhibitor exercise. Sci Rep. 2023;13:14228.
Zarnowski R, Sanchez H, Covelli AS, Dominguez E, Jaromin A, Bernhardt J, Mitchell KF, Heiss C, Azadi P, Mitchell A. Candida albicans biofilm–induced vesicles confer drug resistance via matrix biogenesis. PLoS Biol. 2018;16:e2006872.
Rodrigues ML, Franzen AJ, Nimrichter L, Miranda Ok. Vesicular mechanisms of site visitors of fungal molecules to the extracellular area. Curr Opin Microbiol. 2013;16:414–20.
Zarnowski R, Noll A, Chevrette MG, Sanchez H, Jones R, Anhalt H, Fossen J, Jaromin A, Currie C, Nett JE. Coordination of fungal biofilm improvement by extracellular vesicle cargo. Nat Commun. 2021;12:6235.
Zhang F, Zhao M, Braun DR, Ericksen SS, Piotrowski JS, Nelson J, Peng J, Ananiev GE, Chanana S, Barns Ok. A marine microbiome antifungal targets urgent-threat drug-resistant fungi. Science. 2020;370:974–8.
Zhao M, Zhang F, Zarnowski R, Barns Ok, Jones R, Fossen J, Sanchez H, Rajski SR, Audhya A, Bugni TS. Turbinmicin inhibits Candida biofilm progress by disrupting fungal vesicle–mediated trafficking. J Clin Investig. 2021;131:e145123.
Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N, Verkman A. Dimension-dependent DNA mobility in cytoplasm and nucleus. J Biol Chem. 2000;275:1625–9.
Seksek O, Biwersi J, Verkman A. Translational diffusion of macromolecule-sized solutes in cytoplasm and nucleus. J Cell Biol. 1997;138:131–42.
Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, Lass-Flörl C, Prattes J, Spec A, Thompson GR. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Medicine. 2021;81:1703–29.
Larwood DJ. Nikkomycin Z—prepared to fulfill the promise? J Fungi. 2020;6:261.
Lipa-Castro A, Nicolas V, Angelova A, Mekhloufi G, Prost B, Chéron M, Faivre V, Barratt G. Cochleate formulations of Amphotericin b designed for oral administration utilizing a naturally occurring phospholipid. Int J Pharm. 2021;603:120688.
Fatima I, Rasul A, Shah S, Saadullah M, Islam N, Khames A, Salawi A, Ahmed MM, Almoshari Y, Abbas G. Novasomes as nano-vesicular carriers to reinforce topical supply of fluconazole: a brand new method to deal with fungal infections. Molecules. 2022;27:2936.
Pfaller M, Messer S, Georgopapadakou N, Martell L, Besterman J, Diekema D. Exercise of MGCD290, a Hos2 histone deacetylase inhibitor, together with azole antifungals in opposition to opportunistic fungal pathogens. J Clin Microbiol. 2009;47:3797–804.
Gómez-Garzón M, Gutiérrez-Castañeda LD, Gil C, Escobar CH, Rozo AP, González ME, Sierra EV. Inhibition of the filamentation of Candida albicans by Borojoa patinoi silver nanoparticles. SN Appl Sci. 2021;3:1–8.
Antinori S, Milazzo L, Sollima S, Galli M, Corbellino M. Candidemia and invasive candidiasis in adults: a story evaluate. Eur J Intern Med. 2016;34:21–8.
Thomson DD, Wehmeier S, Byfield FJ, Janmey PA, Caballero-Lima D, Crossley A, et al. Contact‐induced apical asymmetry drives the thigmotropic responses of Candida albicans hyphae. Cell Microbiol. 2015;17:342–54.
Staab JF, Bradway SD, Fidel PL, Sundstrom P. Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1. Science. 1999;283:1535–8.
Almeida RS, Brunke S, Albrecht A, Thewes S, Laue M, Edwards JE Jr, Filler SG, Hube B. The hyphal-associated adhesin and invasin Als3 of Candida albicans mediates iron acquisition from host ferritin. PLoS Pathog. 2008;4:e1000217.
Jimenez-Lopez C, Lorenz MC. Fungal immune evasion in a mannequin host–pathogen interplay: Candida albicans versus macrophages. PLoS Pathog. 2013;9:e1003741.
Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO, Monteagudo C, Lopez-Ribot JL, Milne GT. Inhibition of filamentation can be utilized to deal with disseminated candidiasis. Antimicrob Brokers Chemother. 2006;50:3312–6.
Model A, MacCallum DM, Brown AJ, Gow NA, Odds FC. Ectopic expression of URA3 can affect the virulence phenotypes and proteome of Candida albicans however will be overcome by focused reintegration of URA3 on the RPS10 locus. Eukaryot Cell. 2004;3:900–9.
Pinto AP, Rosseti IB, Carvalho ML, da Silva BGM, Alberto-Silva C, Costa MS. Photodynamic antimicrobial chemotherapy (PACT), utilizing Toluidine blue O inhibits the viability of biofilm produced by Candida albicans at totally different phases of improvement. Photodiagn Photodyn Ther. 2018;21:182–9.
Carvalho ML, Pinto AP, Raniero LJ, Costa MS. Biofilm formation by Candida albicans is inhibited by photodynamic antimicrobial chemotherapy (PACT), utilizing chlorin e6: improve in each ROS manufacturing and membrane permeability. Lasers Med Sci. 2018;33:647–53.
Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol. 2008;6:17–27.
Dickey SW, Cheung GY, Otto M. Completely different medication for dangerous bugs: antivirulence methods within the age of antibiotic resistance. Nat Rev Drug Discovery. 2017;16:457–71.
Allen RC, Popat R, Diggle SP, Brown SP. Concentrating on virulence: can we make evolution-proof medication? Nat Rev Microbiol. 2014;12:300–8.
Henderson J, Nickerson JF. Bacterial endocarditis with Candida albicans superinfection. Can Med Assoc J. 1964;90:452.
Araújo D, Gaspar R, Mil-Homens D, Henriques M, Silva BF, Silva S. Cationic lipid-based formulations for encapsulation and supply of anti-EFG1 2′ O MethylRNA oligomer. Med Mycol. 2021;60:myac030.
Barbosa A, Araújo D, Henriques M, Silva S. The mixed software of the anti-RAS1 and anti-RIM101 2’-O MethylRNA oligomers enhances Candida albicans filamentation management. Med Mycol. 2021;59:1024–31.
Zhao M, Zhang M, Xu Ok, Wu Ok, Xie R, Li R, Wang Q, Liu W, Wang W, Wang X. Antimicrobial impact of extracellular vesicles derived from human oral mucosal epithelial cells on candida albicans. Entrance Immunol. 2022;13:777613.
Toenjes KA, Stark BC, Brooks KM, Johnson DI. Inhibitors of mobile signalling are cytotoxic or block the budded-to-hyphal transition within the pathogenic yeast Candida albicans. J Med Microbiol. 2009;58:779–90.
Okamoto-Shibayama Ok, Sato Y, Azuma T. Resveratrol impaired the morphological transition of Candida albicans beneath varied hyphae-inducing circumstances. J Microbiol Biotechnol. 2010;20:942–5.
Rajasekar V, Darne P, Prabhune A, Kao RY, Solomon AP, Ramage G, Samaranayake L, Neelakantan P. A curcumin-sophorolipid nanocomplex inhibits Candida albicans filamentation and biofilm improvement. Colloids Surf B. 2021;200:111617.
Zhang M, Chang W, Shi H, Zhou Y, Zheng S, Li Y, Li L, Lou H. Biatriosporin D shows anti-virulence exercise via lowering the intracellular cAMP ranges. Toxicol Appl Pharmcol. 2017;322:104–12.
Haque F, Alfatah M, Ganesan Ok, Bhattacharyya MS. Inhibitory impact of sophorolipid on Candida albicans biofilm formation and hyphal progress. Sci Rep. 2016;6:23575.
Nithyanand P, Shafreen RMB, Muthamil S, Pandian SK. Usnic acid inhibits biofilm formation and virulent morphological traits of Candida albicans. Microbiol Res. 2015;179:20–8.
do Nascimento Dias J, de Souza Silva C, de Araújo AR, Souza JMT, de Holanda Veloso Junior PH, Cabral WF, et al. Mechanisms of motion of antimicrobial peptides ToAP2 and NDBP-5.7 in opposition to Candida albicans planktonic and biofilm cells. Sci Rep. 2020;10:10327.
Kim Y-G, Lee J-H, Park JG, Lee J. Inhibition of Candida albicans and Staphylococcus aureus biofilms by centipede oil and linoleic acid. Biofouling. 2020;36:126–37.
Iadnut A, Mamoon Ok, Thammasit P, Pawichai S, Tima S, Preechasuth Ok, et al. In vitro antifungal and antivirulence actions of biologically synthesized ethanolic extract of propolis-loaded PLGA nanoparticles in opposition to Candida albicans. Evid Primarily based Complementary Altern Med. 2019;2019:3715481.
Jalal M, Ansari MA, Ali SG, Khan HM, Rehman S. Anticandidal exercise of bioinspired ZnO NPs: impact on progress, cell morphology and key virulence attributes of Candida species. Artif Cells Nanomed Biotechnol. 2018;46:912–25.
Jalal M, Ansari MA, Alzohairy MA, Ali SG, Khan HM, Almatroudi A, Siddiqui MI. Anticandidal exercise of biosynthesized silver nanoparticles: impact on progress, cell morphology, and key virulence attributes of Candida species. Int J Nanomed. 2019;14:4667–79.
Sudbery PE. Progress of Candida albicans hyphae. Nat Rev Microbiol. 2011;9:737–48.
Han T-L, Cannon RD, Villas-Bôas SG. The metabolic foundation of Candida albicans morphogenesis and quorum sensing. Fungal Genet Biol. 2011;48:747–63.
Ding X, Kambara H, Guo R, Kanneganti A, Acosta-Zaldívar M, Li J, Liu F, Bei T, Qi W, Xie X. Inflammasome-mediated GSDMD activation facilitates escape of Candida albicans from macrophages. Nat Commun. 2021;12:6699.
Puri S, Kumar R, Rojas IG, Salvatori O, Edgerton M. Iron chelator deferasirox reduces Candida albicans invasion of oral epithelial cells and an infection ranges in murine oropharyngeal candidiasis. Antimicrob Brokers Chemother. 2019;63:e02152–02118.
Solar W, Zhang L, Lu X, Feng L, Solar S. The synergistic antifungal results of sodium phenylbutyrate mixed with azoles in opposition to Candida albicans by way of the regulation of the Ras–cAMP–PKA signalling pathway and virulence. Can J Microbiol. 2019;65:105–15.
Cao C, Wu M, Bing J, Tao L, Ding X, Liu X, Huang G. International regulatory roles of the c AMP/PKA pathway revealed by phenotypic, transcriptomic and phosphoproteomic analyses in a null mutant of the PKA catalytic subunit in C andida albicans. Mol Microbiol. 2017;105:46–64.